Trial report in The American journal of drug and alcohol abuse, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 2 syntheses or guidelines pooled it.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Mina M RizkDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-1884-4247
Barbara StanleyMolecular Imaging and Neuropathology Division, New York State Psychiatric Institute, New York, NY, USA.
Tse-Hwei ChooDivision of Biostatistics, New York State Psychiatric Institute, New York, NY, USA.
Martina PavlicovaDepartment of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, USA.
Jennifer M ScodesDivision of Biostatistics, New York State Psychiatric Institute, New York, NY, USA.
John RotrosenDepartment of Psychiatry, New York University Grossman School of Medicine, New York, NY, USA.
Edward V NunesDepartment of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA.
Funding
FLORIDA NODE OF THE DRUG ABUSE CLINICAL TRIALS NETWORKU10DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI METSCH, LISA R, SZAPOCZNIK, JOSE · 2000 to 2015
$56.9M
The National Drug Abuse Treatment Clinical Trials NetworkU10DA013045 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LING, WALTER NMN · 1999 to 2015
$52.6M
CU PARTNERS: NY/LONG ISLAND REGIONAL NODEU10DA013035 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI NUNES, EDWARD V., ROTROSEN, JOHN P · 2001 to 2015
$47.6M
Clinical Trials Network, Ohio Valley Node U10DA013732U10DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI WINHUSEN, T JOHN · 2000 to 2015
$45.0M
The National Drug Abuse Treatment Clinical Trials Network (U10)U10DA015831 · NIDA · MC LEAN HOSPITAL (BELMONT, MA) · PI CARROLL, KATHLEEN M., WEISS, ROGER D. · 2002 to 2015
$28.8M
CLINICAL TRIALS NETWORK: PACIFIC NORTHWEST NODEU10DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI DONOVAN, DENNIS MICHAEL, ROLL, JOHN M. · 2001 to 2015
$25.5M
CLINICAL TRIALS NETWORK MID-ATLANTIC COLLABORATIVE GROUPU10DA013034 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SCHWARTZ, ROBERT P, STITZER, MAXINE L · 1999 to 2015
$25.2M
NIDA CLINICAL TRIALS NETWORK - NYC EAST SIDE NODEU10DA013046 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ROTROSEN, JOHN P · 2000 to 2009
$20.2M
Clinical Trials Network: Southwest NodeU10DA015833 · NIDA · UNIVERSITY OF NEW MEXICO · PI MCCRADY, BARBARA S · 2002 to 2014
$19.9M
Training the Next Generation of Psychiatrists-Scientists for Translational ResearchR25MH129256 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ANTONIA S NEW, Maria De Las Mercedes Perez Rodriguez · 2023 to 2026
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Suicidal ideation in adults with opioid use disorder treated with buprenorphine-naloxone versus extended-release naltrexone. · full record | OpenQuestion